This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Wait With Prostate Cancer When You Can Enjoy Life Cancer-Free?

Prostate cancer is often a slow-growing disease, though current testing cannot accurately quantify individual prognosis. Prostate cancer can turn metastatic, spreading into the lymph nodes, blood, and other organs.

Much is made of the unpleasant side effects of prostate cancer treatment, but as Dr. Samadi reminds, cancer itself is unpleasant. "Unfortunately, cancer impacts the lives of many people, particularly when left untreated. The degree to which varies from one patient to the next, but it is my firm belief that robotic prostatectomy offers the best case scenario for most men." Through his SMART robotic innovations, Dr. Samadi has removed more than 4,000 cancerous prostates.

Urinary continence is restored in 96% of Dr. Samadi's patients just a few months after surgery and erectile function in 85% within 12-24 months. "For most men, SMART surgery makes prostate cancer a very surmountable hurdle. They are cured with minimal, short-term side effects and they go on with their lives in peace."

David Samadi, MD serves as  Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

Related Links: http://www.roboticoncology.com/ http://www.roboticoncology-il.com/ http://www.smart-surgery.com/ http://il.smart-surgery.com/

Related Videos: SMART Robotic Prostate Surgery - David Samadi, MD http://www.youtube.com/watch?v=wRNPA5npn6Y&list=UUZvOHUgjV5EzAS-ZSOBeEGw&index=1&feature=plcp

BREAKING PROSTATE CANCER NEWS - Is The Cost Of Robotic Surgery Justified? http://www.youtube.com/watch?v=Gfe9GGP0tFw&list=UUZvOHUgjV5EzAS-ZSOBeEGw&index=2&feature=plcp

Wait and See Approach to Prostate Cancer - "Watchful Waiting" http://media.roboticoncology.com/tv-interviews/WaitandSeeApproachtoProstateCancer/

 

SOURCE roboticoncology.com

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,076.27 +64.33 0.36%
S&P 500 2,114.07 +4.47 0.21%
NASDAQ 5,099.2310 +22.7070 0.45%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs